Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy

Oncology (Switzerland)

Volumn 82, Issue 5, 2012, Pages 261-268

  Kaneko, Manabu ^a   Nozawa, Hiroaki ^a   Sasaki, Kazuhito ^a   Hongo, Kumiko ^a   Hiyoshi, Masaya ^a   Tada, Noriko ^a   Murono, Koji ^a   Nirei, Takako ^a   Kawai, Kazushige ^a   Sunami, Eiji ^a   Tsuno, Nelson H ^a   Kitayama, Joji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Advanced colorectal cancinoma; Chemotherapy; Neutrophil to lymphocyte ratio; Oxaliplatin; Prognostic factor; Thrombocytosis

Indexed keywords

OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; LABORATORY TEST; LYMPHOCYTE; MALE; NEUTROPHIL; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84860113685     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000337228     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E: Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev 2010; 36:S34-S41.
3. Van Cutsem E, Nordlinger B, Cervantes A: Advanced colorectal cancer: ESMO Clinical Practice Guidelines for Treatment. Ann Oncol 2010; 21:v93-v97.
4. Chau I, Cunningham D: Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009; 100 1704-1719.
5. Wong Y, Meropol N, Speier W, Sargent D, Goldberg R, Beck J: Cost implications of new treatments for advanced colorectal cancer. Cancer 2009; 115: 2081-2091.
6. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008; 454: 436-444.
7. McMillan D: An inflammation-based prognostic score and its role in the nutritionbased management of patients with cancer. Proc Nutr Soc 2008; 67: 257-262.
8. Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998; 176: 335-338. (Pubitemid 28514444)
9. McMillan D, Canna K, McArdle C: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-219. (Pubitemid 36237897)
10. Ishizuka M, Nagata H, Takagi K, Kubota K: Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 2009; 250: 268-272.
11. Chua W, Charles K, Baracos V, Clarke S: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295.
12. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H, Nagata M: High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13: 170-176.
13. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall R: Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203.
14. Gomez D, Farid S, Malik H, Young A, Toogood G, Lodge J, Prasad K: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757-1762.
15. Cho H, Hur H, Kim S, Kim S, Kim J, Kim Y, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58: 15-23.
16. Sarraf K, Belcher E, Raevsky E, Nicholson A, Goldstraw P, Lim E: Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428.
17. Ding P, An X, Zhang R, Fang Y, Li L, Chen G, Wu X, Lu Z, Lin J, Kong L, Wan D, Pan Z: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010; 25: 1427-1433.
18. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN: Blood neutrophilto-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16: 614-622.
19. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L: XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105: 58-64.
20. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Köhne C, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317. (Pubitemid 34704985)
22. Crozier J, McKee R, McArdle C, Angerson W, Anderson J, Horgan P, McMillan D: The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-Fu chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer 2006; 94: 1833-1836. (Pubitemid 43882573)
23. Kelly H, Goldberg R: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-4560. (Pubitemid 46196586)
24. Mitry E, Douillard J, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P: Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-1017. (Pubitemid 39089776)
25. Ji H, Houghton A, Mariani T, Perera S, Kim C, Padera R, Tonon G, McNamara K, Marconcini L, Hezel A, El-Bardeesy N, Bronson R, Sugarbaker D, Maser R, Shapiro S, Wong K: K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006; 25: 2105-2112.
26. Pekarek L, Starr B, Toledano A, Schreiber H: Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995; 181: 435-440.
27. Nozawa H, Chiu C, Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006; 103: 12493-12498. (Pubitemid 44267286)
28. Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M: Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 2003; 163: 2221-2232. (Pubitemid 37466467)
29. Jensen H, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 4709-4717.
30. Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Pérol D, Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13: 1460-1468.
31. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93: 273-278. (Pubitemid 43080028)
32. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla J, Bachelot T, Perol D, Chabaud S, Hogendoorn P, Cassier P, Dufresne A, Blay J: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69: 5383-5391.
33. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M: Pretreatment neutrophil count as an independent prognostic factor in advanced non-smallcell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009; 45: 1950-1958.
34. Maltoni M, Pirovano M, Nanni O, Marinari M, Indelli M, Gramazio A, Terzoli E, Luzzani M, De Marinis F, Caraceni A, Labianca R: Biological indices predictive of survival in 519 italian terminally ill cancer patients. Italian multicenter study group on palliative care. J Pain Symptom Manage 1997; 13: 1-9. (Pubitemid 27063350)
35. Saito T, Kuss I, Dworacki G, Gooding W, Johnson J, Whiteside T: Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1263-1273. (Pubitemid 29282928)
36. Dworacki G, Meidenbauer N, Kuss I, Hoffmann T, Gooding W, Lotze M, Whiteside T: Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001; 7: 947s-957s. (Pubitemid 33600950)
37. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri M, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat F, Saftig P, Levi F, Lidereau R, Nogues C, Mira J, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L: Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059. (Pubitemid 47517504)
38. Youn J, Collazo M, Shalova I, Biswas S, Gabrilovich D: Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012; 91: 167-181.
39. Kandemir E, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M: Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res 2005; 33: 228-235. (Pubitemid 40372439)
40. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel R, Schmid M, Smola M, Stierer M, Tausch C, Galid A, Steger G, Jakesz R: Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003; 89: 1098-1106. (Pubitemid 36798163)
41. Sasaki K, Kawai K, Tsuno N, Sunami E, Kitayama J: Impact of pre-operative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012; 36: 192-200.
42. Sanoff H, Sargent D, Campbell M, Morton R, Fuchs C, Ramanathan R, Williamson S, Findlay B, Pitot H, Goldberg R: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26: 5721-5727.